Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
45 studies found for:    "Microscopic polyangiitis"
Show Display Options
Rank Status Study
1 Unknown  CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors
Conditions: Polyarteritis Nodosa;   Microscopic Polyangiitis
Interventions: Drug: azathioprine;   Drug: cyclophosphamide
2 Active, not recruiting
Has Results
An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Patients With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis
Intervention: Drug: Rituximab
3 Recruiting Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis;   Wegener's
Intervention:
4 Completed CellCept in p-ANCA Vasculitis
Conditions: MPO-ANCA Vasculitis;   Microscopic Polyangiitis
Intervention: Drug: CellCept (mycophenolate mofetil)
5 Recruiting A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis
Condition: Wegener's Granulomatosis or Microscopic Polyangiitis
Interventions: Drug: Methylprednisolone;   Drug: Prednisone;   Drug: Rituximab
6 Completed
Has Results
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
Conditions: Vasculitis;   Wegener's Granulomatosis;   Microscopic Polyangiitis
Interventions: Drug: Rituximab plus cyclophosphamide placebo (rituximab group);   Drug: Cyclophosphamide plus rituximab placebo (control group);   Drug: Azathioprine;   Drug: Methylprednisolone (or other glucocorticoid);   Drug: Prednisone
7 Recruiting A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Condition: Granulomatosis With Polyangiitis
Intervention: Drug: Rituximab
8 Withdrawn BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis
Interventions: Drug: Blisibimod;   Drug: Placebo
9 Completed Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)
Conditions: MPA;   PAN or EGPA With FFS=0;   At Diagnosis or Within the First 15 Days Following Initiation of Corticosteroids
Interventions: Drug: corticosteroid and azathioprine;   Drug: corticosteroid and placebo
10 Completed Efficacy Study of Two Treatments in the Remission of Vasculitis
Conditions: Wegener's Granulomatosis,;   Microscopic Polyangiitis
Interventions: Drug: Rituximab;   Drug: Azathioprine
11 Terminated Plasma Exchange for Renal Vasculitis
Conditions: Wegener's Granulomatosis;   Microscopic Polyangiitis
Interventions: Procedure: Plasma exchange;   Drug: Intravenous methyl prednisolone;   Drug: Methyl prednisolone
12 Active, not recruiting Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis
Conditions: Granulomatosis With Polyangiitis (Wegener's) (GPA);   Microscopic Polyangiitis (MPA)
Interventions: Procedure: Plasma Exchange;   Drug: Glucocorticoids
13 Recruiting Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis
Conditions: Granulomatosis, Wegener's;   Microscopic Polyangiitis
Intervention: Other: blood specimen
14 Unknown  Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis
Interventions: Drug: Glucocorticoids;   Drug: Rituximab
15 Enrolling by invitation Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis
Intervention: Other: Observational
16 Active, not recruiting PRO Development for ANCA Associated Vasculitis
Conditions: Wegener Granulomatosis;   Microscopic Polyangiitis;   Churg-Strauss Syndrome
Intervention:
17 Active, not recruiting Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis;   Renal Limited Forms
Interventions: Drug: Rituximab (Arm B);   Drug: Rituximab (Arm A)
18 Terminated IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis
Conditions: ANCA Associated Systemic Vasculitis Including Wegener’s;   Granulomatosis and Microscopic Polyangiitis and;   Renal Limited Vasculitis
Interventions: Drug: Cyclophosphamide;   Drug: Mycophenolate mofetil;   Drug: Azathioprine;   Drug: Prednisone (and methylprednisolone)
19 Active, not recruiting Rituximab Vasculitis Maintenance Study
Conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis;   Microscopic Polyangiitis;   Wegener Granulomatosis
Interventions: Biological: Rituximab;   Drug: Azathioprine
20 Completed Anti-Cytokine Therapy for Vasculitis
Conditions: Wegener's Granulomatosis;   Renal Limited Vasculitis;   Microscopic Polyangiitis
Interventions: Biological: Infliximab;   Drug: Cyclophosphamide;   Drug: Prednisolone;   Drug: Azathioprine;   Procedure: Plasma exchange;   Drug: Mycophenolate mofetil;   Drug: Methylprednisolone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.